New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma

Thursday May 10th 2012 07:30:07 AM

Consistent progression-free survival improvement shown with continuous lenalidomide therapy in elderly patients not eligible for transplant and as maintenance therapy in patients following autologous stem cell transplant BOUDRY, Switzerland--(BUSINESS WIRE)--May. 10, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from three phase III studies evaluating the use of continuous REVLIMID® (lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant we...

Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel

Monday May 7th 2012 07:30:04 AM

SUMMIT, N.J.--(BUSINESS WIRE)--May. 7, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this position, he will be responsible for global legal strategy at Celgene and will serve on the company’s Management Committee. Mr. Moriarty joins Celgene from Medco Health Solutions where he directed all legal, regulatory, public policy and corporate governance functions as General Counsel and Corporate Secretary since 2008. He also served as President, Global Pharmaceutical Strategies, Senior Vice President, Pharma Strategies & Solu...

Celgene Corporation to Present at Two Upcoming Investor Conferences

Friday May 4th 2012 07:30:53 AM

SUMMIT, N.J.--(BUSINESS WIRE)--May. 4, 2012-- Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company’s Web site at www.celgene.com. Celgene management will provide an overview of the Company. Tuesday, May 8, 2012 Celgene will present at the Baird 2012 Growth Stock Conference at 12:20 p.m. ET. Thursday, May 17, 2012 Celgene will present at the Bank of America Merrill Lynch 2012 Health Care Conference at 11:40 a.m. ET. About Celgene ...

Celgene Reports First Quarter 2012 Operating and Financial Results

Thursday April 26th 2012 07:03:42 AM

-- Non-GAAP Net Product Sales of $1.25 Billion, Increased 17 Percent Y/Y -- Non-GAAP Total Revenue of $1.27 Billion, Increased 15 Percent Y/Y -- Non-GAAP Diluted Earnings Per Share of $1.08, Increased 30 Percent Y/Y -- 2012 Revenue and Earnings Guidance Reaffirmed SUMMIT, N.J., Apr 26, 2012 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales of $1,245 million for the first quarter of 2012, a 17 percent increase from the same period in 2011. Non-GAAP net income for the first quarter of 2012 increased 23 percent to $484 million ...

Celgene Corporation to Announce First Quarter 2012 Results on April 26, 2012

Tuesday April 17th 2012 07:32:32 AM

SUMMIT, N.J., Apr 17, 2012 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 26, 2012 at 9 a.m. ET to discuss the company's first quarter 2012 financial and operational results. The webcast will be available in the investor relations section of the Company's Web site at www.celgene.com. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory dis...

Celgene Completes Acquisition of Avila Therapeutics

Thursday March 8th 2012 07:30:51 AM

SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 8, 2012-- Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350 million in cash, plus up to $575 million contingent upon certain milestones related to AVL-292 and candidates from Avila’s discovery program. The transaction provides Celgene with a highly-selective Bruton’s tyrosine kinase inhibitor, currently in phase I clinical development, as well as a unique discovery platform, Avilomics™, for developing targeted covalent drugs that treat diseases through protein silencing. ...

Celgene Corporation to Present at Two Upcoming Investor Conferences

Monday February 27th 2012 07:30:14 AM

SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 27, 2012-- Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company’s Web site at www.celgene.com. Celgene management will provide an overview of the Company. Tuesday, March 6, 2012 Celgene will present at the Cowen & Company 32nd Annual Health Care Conference at 8:40 a.m. ET. Tuesday, March 13, 2012 Celgene will present at the Barclays Capital Global Healthcare Conference at 4:45 p.m. ET. About Cel...

Celgene Corporation to Present at the Citi 2012 Global Health Care Conference

Tuesday February 21st 2012 07:30:50 AM

SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 21, 2012-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Citi 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 9:30 a.m. EST will be webcast live and will be available in the investor relations section of the Company’s Web site at www.celgene.com. Celgene management will provide an overview of the Company. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the ...

Celgene Reports Record Fourth Quarter and Full Year 2011 Operating and Financial Results

Thursday January 26th 2012 07:30:11 AM

- Total Revenue of $4.8 Billion, Increased 34 Percent Y/Y - Non-GAAP Diluted Earnings Per Share of $3.79, Increased 36 Percent Y/Y - Confirms 2012 Outlook SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 26, 2012-- Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales of $1,241 million for the fourth quarter of 2011, a 21 percent increase from the same period in 2010. Non-GAAP net income for the fourth quarter of 2011 increased 38 percent to $473 million compared to $343 million in the fourth quarter of 2010. For the same periods, Non-GAAP diluted earnings per share increased 46 perc...

Celgene to Acquire Avila Therapeutics

Thursday January 26th 2012 07:25:11 AM

Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases Avilomics™ Platform enhances drug discovery capabilities SUMMIT, N.J. and BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 26, 2012-- Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc. The acquisition positions Celgene to expand its leading role in the future treatme...